Trial Profile
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Clear cell sarcoma; Colorectal cancer; Gallbladder cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 27 Apr 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 27 Apr 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.
- 27 Apr 2021 Status changed from recruiting to active, no longer recruiting.